I. MODIFIED AGREEMENTS

Company*
(Country;
Symbol)

Company*
(Country;
Symbol)

Change from original agreement

Terms/Details (Date)

Celgene
Corp.
(CELG)

Pharmion Corp. (PHRM)

Amended deal gives Pharmion additional thalidomide rights in Asia, and extends R&D deal from 2005 to 2007

Pharmion is making a one-time $77M payment, and will see its supply and royalty rate reduced from 36% to 23.5% of sales; Pharmion also is paying $3M for the additional Asian territories and $8M to support the collaboration (12/3)

Genelabs
Technologies
Inc.
(GNLB)

Affymetrix Inc. (AFFX)

They amended license to Genelabs' Linker-Aided DNA Amplification technology

Affymetrix paid $1.25M for a fully paid up nonexclusive license that eliminates royalties and fees payable under the original December 2002 agreement (12/30)

Mergen Ltd.*

Oxford Gene Technology Ltd.* (UK)

Agreement resolving patent infringement litigation between the companies

Mergen has obtained a license from OGT for its expression chips in the U.S., Europe and Japan, allowing it to make and sell microarrays (1/20)

XOMA Ltd.
(XOMA)

Genentech Inc. (NYSE:DNA)

They restructured terms of their deal covering Raptiva, which is approved for treating plaque psoriasis

XOMA opted to take a mid-single-digit royalty on sales, and won't be responsible for funding any development or marketing activities; XOMA no longer is obliged to repay a $40M development loan (1/12)

II. TERMINATED AGREEMENTS

Generex
Biotechnology
Corp.
(Canada;
GNBT)

Charmed Capital plc

They ended a proposed deal for the marketing of Generex diabetes products in India, China and Australia

The deal would have included a $6M investment from Charmed Capital; Generex said it will seek partnerships with pharmaceutical companies instead (11/26)


Notes:

* Private companies are indicated with an asterisk.

Unless otherwise noted, stock symbols listed are on the Nasdaq market.

NYSE = New York Stock Exchange.

No Comments